已收录 268921 条政策
 政策提纲
  • 暂无提纲
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
[摘要] Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in females and is also associated with sexual dysfunction and bone loss. These side effects increase risk of antipsychotic nonadherence and suicide and pose significant problems in the long term management of women with schizophrenia. In this manuscript, we review the literature on prolactin; its physiology, plasma levels, side effects and strategies for treatment. We also present the rationale and protocol for an ongoing clinical trial to treat symptomatic hyperprolactinemia in premenopausal women with schizophrenia. More attention and focus are needed to address these significant side effects and help the field better personalize the treatment of women with schizophrenia.
[发布日期] 2013-08-22 [发布机构] 
[效力级别]  [学科分类] 
[关键词] Women;Prolactin;Amenorrhea;Galactorrhea;Clinical trial;Sexual dysfunction;Osteoporosis;Aripiprazole [时效性] 
   浏览次数:4      统一登录查看全文      激活码登录查看全文